Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00216177
Status:
UNKNOWN
Last Update Posted:
2009-08-18
First Post:
2005-09-20
Brief Title:
Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis
Sponsor:
Hvidovre University Hospital
Organization:
Hvidovre University Hospital
Study Overview
Official Title:
Randomised Multicenter Open-label Parallel-group Study Comparing Adalimumab 40 mg sc Eow Versus Infliximab 3 mgkg iv Every 6 Weeks in Rheumatoid Arthritis Patients With Unsustainable Clinical Response to Infliximab 3 mgkg Every 8 Weeks
Status:
UNKNOWN
Status Verified Date:
2009-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to establish whether RA patients with moderate to severe disease activity with unsustainable response to infliximab 3 mgkg every 8 weeks have better efficacy with adalimumab 40 mg sc eow compared to infliximab 3 mgkg iv every 6 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT no 2005-001633-14 | None | None | None |
| SwitchHUM 05-001 | None | None | None |